New scan could predict which brain tumors will shrink

NCT ID NCT05376878

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This pilot study tests a special PET/MRI scan that uses a radioactive tracer to find HER2+ breast cancer that has spread to the brain. The scan aims to show whether the cancer cells take up the tracer, which might predict if they will respond to the standard drug trastuzumab deruxtecan. Ten women with HER2+ breast cancer and brain metastases will be scanned before starting treatment. The goal is to see if the scan can help guide therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
64Cu-DOTA-Trastuzumab (a radioactive tracer for imaging)
What this could lead to
If successful, this scan could help doctors see which brain metastases will respond to trastuzumab deruxtecan, guiding personalized treatment.
What could go wrong
This is a very small pilot study (10 people) focused on imaging, not treatment. The scan may not reliably predict outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.